Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 9/20 | 0.65 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403852 | 0.85 | SLC9A1 (0.63) | SLC9A1RPS6KA3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14953637 | 0.82 | SLC9A1 (0.66) | SLC9A1RPS6KA3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19257743 | 0.82 | SLC9A1 (0.67) | SLC9A1ALDH1A1GRM2NPC1MAPT | |
| SCHEMBL9618157 | 0.81 | RPS6KA3 (0.84) | SLC9A1RPS6KA3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5550585 | 0.81 | RPS6KA3 (0.64) | SLC9A1RPS6KA3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19154177 | 0.81 | SLC9A1 (0.59) | SLC9A1RPS6KA3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2494163 | 0.80 | RPS6KA3 (0.77) | SLC9A1RPS6KA3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5421073 | 0.80 | SLC9A1 (0.63) | SLC9A1RPS6KA3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6846943 | 0.80 | SLC9A1 (0.69) | SLC9A1ALDH1A1GRM2NPC1MAPT | |
| SCHEMBL45852 | 0.79 | SLC9A1 (1.00) | SLC9A1POLBGRM2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119562993-A | Has low volatile organic compound conformal coating of object content | 雅客纳米公司 | 2025-03-04 | — | — | CN | claimed |
| US-20260139196-A1 | RUST-PREVENTIVE LUBRICATING OIL COMPOSITION | HI LEX CORP (JP) | 2026-05-21 | — | — | US | disclosed |
| EP-4700821-A1 | TREATMENT SOLUTION AND METHOD FOR TREATING OBJECT TO BE TREATED | FUJIFILM Corporation (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20260028558-A1 | TREATMENT LIQUID AND METHOD FOR TREATING OBJECT TO BE TREATED | FUJIFILM CORP (JP) | 2026-01-29 | — | — | US | disclosed |
| US-12481218-B2 | Treatment liquid, method for washing substrate, and method for removing resist | FUJIFILM CORPORATION (JP) | 2025-11-25 | — | — | US | disclosed |
| US-12441965-B2 | Treatment liquid and substrate washing method | FUJIFILM CORPORATION (JP) | 2025-10-14 | — | — | US | disclosed |
| CN-113861256-B | Preparation method and application of 16, 17-dihydroxysteroid compound | 天津药业研究院股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-116171317-B | Aqueous composition for lubrication of motorized systems | 道达尔能源万泰克公司 | 2025-06-17 | — | — | CN | disclosed |
| US-12275921-B2 | Treatment liquid and substrate treatment method | FUJIFILM CORPORATION (JP) | 2025-04-15 | — | — | US | disclosed |
| CN-115989314-B | Treatment liquid and method for treating substrate | 富士胶片株式会社 | 2025-04-15 | — | — | CN | disclosed |
| CN-105359070-A | Laminate for touch panel, and touch panel | FUJIFILM CORP | 2016-02-24 | — | — | CN | disclosed |
| US-8853278-B1 | Compositions comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2321316-B1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20110144132-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2138492-A1 | Substituted pyrimidin-4-one derivatives | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009156865-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-12-30 | — | — | WO | disclosed |
| US-20090003742-A1 | Grease Composition For Hub Unit Bearing, And Hub Unit Bearing For Vehicle | NSK LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| EP-1244653-A1 | NON PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1127875-A1 | Process for the preparation of alpha-dimethylaminomethyl-tryptophan methyl ester | WARNER-LAMBERT COMPANY (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2001046176-A2 | NON PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028558-A1 | TREATMENT LIQUID AND METHOD FOR TREATING OBJECT TO BE TREATED | AOC1, EPCAM, AOC2 | SLC9A1 347/4885RPS6KA3 4578/4885CYP1A2 2570/4885 |
| US-20110144132-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | TYMP, DHFR, DPYD | SLC9A1 703/4885RPS6KA3 2113/4885CYP1A2 1136/4885 |
| US-20260139196-A1 | RUST-PREVENTIVE LUBRICATING OIL COMPOSITION | SRRT, SCD, SUGT1 | SLC9A1 1992/4885RPS6KA3 2453/4885CYP1A2 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.